MicroRNAs (miRNAs) are small non-coding RNAs that regulate various aspects of gene expression in physiology and development. Links between miRNAs and the initiation and progression of human diseases are becoming increasingly apparent. The development of methods to detect the subcellular and tissue localization of miRNAs is essential for understanding their biological role in homeostasis. In this review, we discuss how in situ hybridization can complement tissuelevel miRNA expression profiling and its role as an investigational tool to better understand the etiology of human diseases. Furthermore, in situ hybridization of miRNAs represents a potent diagnostic assay that could be further refined and utilized for clinical applications. 
Introduction microRnAs (miRnAs) are a class of endogenous non-coding
RnAs (ncRnAs) that are highly conserved among species and are essential to many physiological and pathophysiological processes [1, 2] . miRnAs are transcribed, by RnA polymerase II or III, as longer primary transcripts that are further processed to form hairpin loop structures and undergo maturation through a series of catalytic steps. In the cytoplasm, mature miRnAs are integrated into the RnA-induced silencing complex (RISc) and are incorporated with messenger RnA (mRnA) [3, 4] . Perfect or nearperfect complementarity between miRnA and its target mRnA has been found to induce mRnA degradation by RISc; partial complementarity has been found to repress mRnA translation by blocking ribosomal access to the mRnA [5] . Because of the "power" miRnAs have to control gene expression, they are involved in a wide range of developmental processes, cell-cycle regulation, and the control of cell fate [6] . Studies of miRnA expression have revealed tissue-or cell-specific expression patterns, and the deregulation of miRnA expression and activity has been correlated with the pathogenesis of a variety of human genetic diseases, e.g., cancer, cardiovascular disease, diabetes, and neurodegenerative disorders [6] [7] [8] [9] [10] [11] .
In situ hybridization (ISH) is a powerful tool that can provide invaluable insights into physiological and pathological processes by identifying the expression level and localization of specific miRnA within individual cells in tissue sections. In this review, we first provide an overview of miRnA ISH using locked nucleic acid (LnA)-modified probes and the recent progressions in this technology.
Secondly, we briefly compare the different miRnA profiling methods associated with LnA-ISH. Finally, we discuss the recent use of ISH to research the pathology of various human diseases.
LnAs and miRnA ISH

Physicochemical properties of LNAs
LnAs comprise a class of bi-cyclic, high-affinity RnA analogues in which the furanose ring of LnA monomers is conformationally locked in an RnA-mimicking c3'-endo (N-type) conformation [12, 13] . LnA is defined as an oligonucleotide containing at least one LnA monomer (i.e., one 2'-O,4'-C-methylene-β-dribofuranosyl nucleotide). LnA is a versatile tool possessing basic physicochemical properties that are essential for practical utilization, which include good aqueous solubility and a full compatibility with standard coupling chemistry and synthesis programs of commercial DnA synthesizers. Furthermore, LnA monomers are fully compatible with other monomers and can be readily combined with them (e.g., DnA, RnA, 2'-O-meRnA, and 2'-O-mOE-RnA) and/or with phosphorothioate or phosphodiester linkages [14, 15] .
Several studies have demonstrated that LnA-modified oligonucleotides exhibit unprecedented thermal stability when hybridized with their RnA target molecules [16, 17] . An increase in melting temperature (tm) of 2-10 °c per monomer against complementary RnA, compared with unmodified duplexes, has been reported. the observed relative increase in tm per LnA monomer in LnA:DnA mixmers reaches a maximum for oligonucleotides containing less than 50% LnA monomers [18, 19] . Importantly, LnA incorporation improves mismatch discrimination compared to unmodified reference oligonucleotides. LnA-modified oligonucleotides follow
Watson-crick base pairing rules and mediate high-affinity hybridization without compromising base pairing selectivity.
In addition, LnA oligonucleotides display high stability and low toxicity in biological systems, efficient transfection into the system should be checked using a positive control probe and one or two negative control probes.
the two most critical steps in the miRnA ISH protocol are the target demasking step, often known as the "predigestion" or "proteinase-K" step, and the hybridization step. the proteolytic digestion step is based on the use of relatively unspecific cleavage of tissue components by proteases, such as proteinase K or pepsin. Proteolytic digestion of the tissue provides access to the miRnAs in the tissue matrix. the optimal level of proteinase K treatment depends on the extent of fixation.
Specific probe hybridization requires a well-defined and stable hybridization buffer, a stable hybridization temperature, and an optimal probe concentration. the hybridization buffer must have an optimal level of salts, oligonucleotide stabilizers (i.e., inert RnA or DnA), viscosity-reducing agents (e.g., dextran and Denhardt's solution), and denaturing agents (e.g., formamide).
Successful miRnA ISH using LnA probes has been reported with concentrations of formamide ranging from 25% to 70% [23, 30, 32] . A formamide-free hybridization buffer has been developed which allows detection of miRnAs with LnA probes at a high signal-to-noise ratio [22] .
Development of miRNA ISH assays
A few methods have been reported to be able to amplify the ISH signal when low copy numbers of miRnA need to be detected. the catalyzed reporter deposition (cARD) method is based on the deposition of biotinylated tyramine (Bt) at the location of the probe label through the enzymatic action of horseradish peroxidase [33] . the Bt precipitate can then be visualized with mammalian cells, good aqueous solubility, and potent antisense activity in vivo [20] .
miRNA ISH protocols
Detection of miRnA in tissue sections by ISH is required to understand the details of how individual miRnAs function in tissue homeostasis, development, and disease. ISH technology allows for the quantitative detection of expression at the cellular level. the generally fragile nature of RnA and the small size of miRnAs are two main parameters that make ISH a challenging technology. In contrast to ISH analysis of mRnA, which is most often performed using long antisense and sense probes obtained by in vitro transcription, in situ detection of miRnAs requires alternative methods for both detection and specificity analysis. the employed protocols generally include proteolytic digestion, post-fixation, acetylation, hybridization, or signal amplification and detection ( Figure 1 ).
As was described above, the high affinity and excellent discrimination of short LnA oligonucleotides make them well suited for various miRnA detection and analysis techniques, including microarray analysis, qPcR, micromagnetic beadbased hybridization, and ISH. the use of LnA:DnA chimeric probes for ISH analysis has led to a series of detection strategies for chromogenic and fluorescence detection. Different types of tissues can be used, including paraffin sections [21] [22] [23] , cryostat sections [24] [25] [26] [27] , whole-mount specimens [28, 29] , and cultured cells [26, 30, 31] . For successful detection of miRnAs, formalin- polymerase chain reaction (qRt-PcR) [41, 42] , bead-based hybridization [43] , and deep sequencing [44, 45] (Figure 2 ).
However, miRnA expression is, in many cases, highly cell-type specific, and none of these methods identify which cells those miRnAs are expressed in. ISH technique is the only method that allows direct assessment of the distribution of particular miRnAs at the cellular and subcellular levels.
Deep sequencing
When applied to miRnA profiling, deep sequencing methods have high sensitivity and the potential to discover novel ncRnAs.
Deep sequencing allows the simultaneous sequencing of several different RnA molecules, including small RnAs [45] . the existing deep sequencing platforms differ by the chemistry principles used, approach to amplification, efficiency, duration, expense, accuracy, error distribution, and tolerance of minimum sequence length (from 13 to 250 base pairs) [46, 47] . Deep sequencing technologies are not subject to the problems of background noise and cross hybridization, compared with other high-throughput assays like microarray [47] . Information gained via deep sequencing reflects the actual miRnA profile, and de novo sequencing allows the discovery of miRnAs or ncRnAs not previously identified by cloning or sequencing [48] . Deep sequencing also allows for the detection of allelespecific expression of miRnA, and relative quantification of the guide vs. passenger strands of miRnAs. Key challenges of the deep sequencing method include the requirement for at least 10 ug of high-quality RnA, as the purification steps lead to a loss of material. Deep sequencing methods are also expensive for routine laboratory work. As they become more affordable, their use will become more widespread [44, 48] . the "third generation" of sequencing, which will soon be available, is based on nanopore technology and will be able to read the diploid mammalian genome in approximately 24 hours at much lower costs than second-generation sequencing, which requires 4-5 days [49] .
miRNA microarray analysis microarray analysis allows the simultaneous testing of multiple genes in numerous samples, provides a large amount of information, and saves time. It is now recognized that this method should be used only as a first step in miRnA expression screening and should be followed by other profiling techniques for validation purposes, such as qRt-PcR [40] . many types of microarray are available that are based on distinct principles and technologies that vary in preparation steps, hybridization steps, and final application. microarrays also differ by the surface used (glass or quartz); how probes are spotted (hand or machine), designed (a difficult task because of the small size of miRnAs), synthesized (possibly directly on the surface), and modified; and the amount of probe or sample that is needed. the aim of each experiment dictates the type of array used [40, 50, 51] . methods of miRnA expression profiling miRnA expression profiling has been a key component of miRnA studies. It can be applied to disease prognosis, it may be used to define disease markers, and, in some cases, it can be used to predict cancer therapy outcome [36, 37] . numerous techniques are available for gaining information about miRnA signatures; the most frequently used methods are presented in table 1.
northern blot analysis [38, 39] was first used for gene expression detection and quantification of miRnA before the development of other techniques. the first high-throughput technology was miRnA microarray analysis, which was initially developed in carlo croce's laboratory [40] . Other than microarray, frequently used strategies for miRnA profiling are quantitative real-time need for large amounts of RnA. In fact, the PcR-based miRnA profiling method can detect miRnAs with very low copy numbers [41] , which is important because the RnA from clinical samples may be very limited. Advantages of qRt-PcR-based techniques are its high levels of sensitivity, specificity, and affordability [53] .
qRt-PcR also offers the possibility of early cancer diagnosis, detection of disease progression, cancer classification (when histopathological findings are indeterminate), screening for RnA genes responsible for diseases, and a new approach in monitoring treatment efficacy [53, 54] . miRnA expression analysis by qRt-PcR technique is also widely used to confirm the most significant results obtained from miRnA microarray genome-wide profiling [53] . However, qRt-PcR has some technical limitations. It requires the input of good-quality RnA, has a complicated reverse transcriptase step, and inter-batch variability.
miRNA ISH with LNA probes
miRnA ISH is the only method that renders the location of RnA visible on a histology section. Briefly, ISH detects miRnA by facilitating a reaction between the miRnA and the labeled miRspecific LnA probes. the greatest strengths of the technique are its ability to preserve RnA integrity (no cell lysis is performed) and identify the actual locations of miRnA inside tissues or cell compartments [35] . the efficiency of ISH depends on the miRnA copy number (the higher the better), probe length and concentration, and hybridization set-up conditions (i.e., stringency) [28, 35] . the several published protocols differ mainly in regard to the necessity of protease prehybridization, the molecule used for labeling the probes (fluorescein isothiocyanate or digoxigenin), probe concentration, hybridization temperature amplification, reverse transcription, and/or enrichment of small RnAs [40] .
Bead-based hybridization
the advantages of the bead-based hybridization method for miRnA profiling are its high specificity, sensitivity, and efficiency [43] . the protocol starts by ligation of an adaptor molecule to a small RnA, which is followed by adaptor-specific reverse transcription (i.e., primers aligning to the adaptor) and then PcR amplification with primers antisense to the adaptor sequence is being subsequent (one of which is labelled with biotin). the biotinylated PcR product is then hybridized with miRnA-specific probes bound to fluorescent beads. Known miRnA-specific signals that are produced together with the beads and marked PcR products are measured and read by a flow cytometer. For each known miRnA, a complementary probe and mixture of fluorescent dyes have been made to distinguish and decipher the miRnA when its signal is detected [43, 52] . the bead-based hybridization technique is time-consuming and strenuous. As with miRnA microarrays, this method is limited in that only known miRnAs can be detected, but it has the advantage that all known miRnAs can be assayed in a single run [52] , and the RnA input required can be as low as 100 ng. Although this technique is not as commonly used as other miRnA profiling techniques, the accuracy and reliability of the miRnA expression profiles generated by this technique are highly comparable to profiles gained with qRt-PcR or direct sequencing [43] .
miRNA qRT-PCR
PcR-based profiling is the ideal solution for some of the problems encountered with microarray profiling, for instance the and duration, and the requirement for signal amplification [35] .
common problems in LnA-based ISH are a strong background signal and/or a weak miRnA signal, which is especially prevalent in samples containing low miRnA copy numbers. these issues can be resolved by increasing the probe concentration or introducing an amplification step [35] . Although ISH is a lowthroughput approach (one probe per miRnA), it is the only miRnA profiling technique that can evaluate miRnA expression in fixed tissues, cells, and circulating tumor cells and that can be used to screen for single miRnA molecules in human cancer tissue sections and animal embryos [28, 30] . Furthermore, this method can be expanded to identify different ncRnAs.
miRnA ISH application in human diseases
Cancer miRnA genes are most often located at fragile sites, which frequently undergo loss of heterozygosity (LOH), amplification, and breakages. this is one observation that supports the hypothesis that miRnAs may be dysregulated in human cancers [55] . Hundreds of expression profiling studies have also shown that tumors ubiquitously exhibit dysregulated miRnA expression patterns relative to corresponding normal tissue.
Patterns of miRnA expression provide useful information for tumor classification and prognosis [56] . nevertheless, as miRnA expression is, in many cases, highly cell-type specific, the results of such profiling studies must be interpreted cautiously prostate, bile duct, and stomach cancers [57, 58] . Yamamichi et al. [59] found that miR-21 was much more highly expressed in colorectal tumors than in normal colonic mucosa. they also observed, using ISH, that miR-21 was expressed in cancerassociated stromal fibroblasts and that the frequency and extent of miR-21 expression increased during the transition from precancerous colorectal adenoma to advanced carcinoma. Also using ISH, Dillhoff et al. [60] showed that miR-133a levels were very low in the infarcted and peri-infarcted myocardium [71] . Using ISH on carotid arteries in vitro and in vivo, torella et al. [72] ISH has not been routinely performed in studies on cardiac miRnA function, likely due to the challenging and tedious nature of the protocols. Schneider et al. [76] reported the development of a markedly improved approach combining fluorescencebased miRnA-ISH with IHc. they applied this protocol to differentiating embryoid bodies (EBs), as well as to embryonic and adult mouse hearts, to detect miRnAs that were upregulated during EB cardiomyogenesis, as determined by array-based miRnA expression profiling [76] . the authors found specific colocalization of miR-1 in myosin-positive cells (cardiomyocytes) of EBs of developing and mature hearts. In contrast, miR-125b and miR-199a did not localize to cardiomyocytes, as previously suggested for miR-199a, but were rather expressed in connective tissue cells of the heart. more specifically, by co-staining with α-smooth muscle actin (α-SmA) and collagen-I, they found that miR-125b and miR-199a localize to perivascular α-SmA(-) stromal cells [76] . their findings highlight the importance of determining exact cell-specific localization of miRnAs by sequential miRnA-ISH and IHc for all studies aiming at understanding the role of miRnAs and their targets.
Neurodegenerative diseases
Recent miRnA expression profiling studies have revealed that some miRnAs are aberrantly expressed in the brains of patients with neurodegenerative disorders, such as Huntington's disease (HD), Parkinson's disease (PD), and Alzheimer's disease (AD) [77] . 
Cardiovascular diseases
miRnAs play an essential role in cardiovascular biology and are often dysregulated in several heart diseases, including myocardial hypertrophy, heart failure, and arrhythmia [68] . these deregulations can be caused by aberrant expression of genes from the miRnA biogenesis machinery. For instance, a very low level of Dicer expression was observed in patients with end-stage dilated cardiomyopathy and/or heart failure, and significantly elevated Dicer expression was found in recovering hearts after installation of a left ventricular assist device [69] .
Dysregulation can also be caused by aberrant expression of miRnAs themselves (e.g., deregulation of miR-1 and miR-133 in cardiac hypertrophy and arrhythmia) [68] .
Profiling studies have identified that some are miRnAs differentially regulated during cardiac development and disease, while their distinct cell-specific localization remains largely undetermined. In this regard, ISH analysis is the most powerful, as it can provide the specific localization of regulated miRnA and will also be prerequisite for subsequent unraveling of the importance and function of each miRnA in relation to cardiac development.
It is known that miR -1, miR-133a, miR-133b, miR-206, miR208a, miR-208b , and miR-499 are muscle-specific miRnAs.
Among them, miR-133b and miR-206 are only expressed in skeletal muscle and miR-208a is only expressed in cardiac muscle [70] . miRnA microarray analysis of the heart from a mouse model of myocardial infarction indicated that the levels of miR-1, miR-133a, miR-208a, and miR-499 were significantly reduced in the infarcted myocardium [71] . ISH of miR-133a also Unauthenticated Download Date | 9/7/17 3:38 AM [90] have reported that levels of several miRnAs with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls. One of these, miR-9 and miR-9*, which are decreased early in HD, are processed from the same primary transcript from three genomic loci (miR-9-1, miR-9-2, and miR-9-3). miR-9-1 and miR-9-3 both have upstream RE1 sequences that can be occupied by RESt.
Interestingly, miR-9/miR-9* targets two components of the RESt complex: miR-9 targets RESt and miR-9* targets coRESt. these data provide evidence for a double negative feedback loop between the RESt silencing complex and miR-9/miR-9* [90] . ISH analysis also found that MiR-9 is highly expressed in the ventricular zone of the developing brain, which contains neural stem cells, but it is not expressed in the roof plate or the floor plate [91] . Over-expression of miR-9 negatively regulates the Hes1 protein expression by interacting with the 3′-UtR of Hes1 mRnA, thereby inducing cell cycle exit and neuronal differentiation.
It should be noted that the field of miRnAs in neurodegeneration is still in its earliest stages [78, 92] [79] . When ISH was performed for miR-107 in human brains, it was found that miR-107 is expressed in both neurons and astrocytes but is enriched in neurons. Perhaps most importantly, unlike other miRnAs, the expression of miR-107 decreased disproportionately in particular laminae of neurons that were most affected by an AD pathology. nelson et al. [88] performed ISH with special focus on the human entorhinal cortex Other than miRnAs, long ncRnA (lncRnAs), a very heterogeneous group of ncRnAs that are more than 200 nucleotides in length, have attracted attention [94, 95] .
LncRnAs are related to transcriptional regulation or mRnA processing, characteristics shared with miRnAs. Unlike miRnAs, however, lncRnAs have more complex functions and a wider spectrum of biological contexts. many of these transcripts have been shown to exhibit cell type-specific expression, localize to subcellular compartments, and associate with the pathogenesis of human diseases. In our laboratory, we designed LnA-specific probes and analyzed the expression of some cancer-related lncRnAs in human FFPE or frozen samples. We found that one type of lncRnAs has much higher expression in microsatellite-stable colorectal tumors but lower expression in microsatellite-unstable colorectal tumors and adjacent normal colon tissue.
In conclusion, both theory and practical experience identify 
